Editorial: The predictive benefits of inflammatory markers in cancers of the liver.

This article is an editorial that discusses the potential benefits of using inflammatory markers in the diagnosis, prognosis, and treatment response prediction of liver cancers, specifically hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). The authors highlight the importance of accurate pre-intervention prognostication and personalized treatment approaches for liver cancer patients. They also discuss various studies that have investigated the role of inflammatory markers, such as serum markers, gene signatures, and inflammation-based scores, in predicting HCC recurrence, survival, and treatment outcomes. Additionally, the article mentions the potential use of immune checkpoint inhibitors and tyrosine kinase inhibitors in combination with transcatheter arterial embolization (TACE) for unresectable HCC. The authors conclude that identifying reliable prognostic inflammatory markers is crucial for improving outcomes in liver cancer patients. [Extracted from the article]